Navigation Links
Uroplasty To Present At The 25th Annual ROTH Growth Stock Conference
Date:3/7/2013

MINNEAPOLIS, March 7, 2013 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, announced today that David Kaysen , President and CEO, and Darin Hammers , Vice President of US Sales, will present the Company's business strategy and financial results at the 25th Annual ROTH Growth Stock Conference at 8:30 AM PT on Monday, March 18, 2013 at The Ritz Carlton in Dana Point, CA.

Attendance at the conference is by invitation only. A live audio webcast of the presentation will be broadcast via the Internet. Those interested in listening to the webcast may access it at http://wsw.com/webcast/roth27/upi/ or through Uroplasty's website at www.uroplasty.com. An archived replay of the presentation will be available for 90 days.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions.  Our primary focus is the commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared neuromodulation system that delivers percutaneous tibial nerve stimulation for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence.  We also offer Macroplastique® Implants, a urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due
'/>"/>

SOURCE Uroplasty, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Uroplasty Announces Executive Changes In US Sales Organization
2. Uroplasty Reports Fiscal Third Quarter 2013 Financial Results
3. Uroplasty To Participate In The Oppenheimer 23rd Annual Healthcare Conference
4. Uroplasty To Participate In Two Upcoming Investor Conferences
5. Uroplasty Reports Fiscal Second Quarter 2013 Financial Results
6. Uroplasty To Participate In Two Upcoming Conferences
7. Uroplasty Reports Fiscal First Quarter 2013 Financial Results
8. Uroplasty to Issue First Quarter of Fiscal 2013 Financial Results on July 26, 2012
9. Uroplasty To Present At The JMP Securities Healthcare Conference
10. Uroplasty Reports Fiscal Fourth Quarter And Full Year 2012 Financial Results
11. Uroplasty Announces Product Development and New Clinical Trial Initiatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... of, collaboration with investigators worldwide to develop new treatments for ... diverse forms of cancer ... on relapse rate of patients with early-stage breast cancer, - Four oral ... results of RECORD-1 study in renal cell ...
... Mich. and TOULOUSE, France, May 15 ... company,developing HDL-related compounds for the treatment of ... has completed a Phase I,clinical trial for ... candidates.,CER-002 is a peroxisome proliferator-activated receptor (PPAR),delta-specific ...
Cached Medicine Technology:Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease 2
(Date:4/24/2014)... Ever since it was first identified more than ... to play an integral role in preventing the onset ... either lost or mutated, malignant cells can grow unchecked ... by investigators at Beth Israel Deaconess Medical Center (BIDMC) ... effects and how its loss or alteration can set ...
(Date:4/24/2014)... TORONTO Baker,s yeast is giving scientists a better ... of hospitalization and illness world-wide. , When two ... one can suppress or enhance the effectiveness of the ... of another. These types of interactions are a major ... severe practical limits on the practical scope of drug ...
(Date:4/24/2014)... stressful outcomes for parents who have a child born ... a recent study led by a researcher at the ... and life-changing and stress levels high, the vast majority ... positive outcomes as well, a phenomenon known as posttraumatic ... of the American Journal of Orthopsychiatry . , ...
(Date:4/24/2014)... 24, 2014 ,Take me out to the ballgame, ... kale chips. The more likely culprits include French fries, ... Unfortunately for children who play youth baseball, eating unhealthy ... weight problems, according to researchers at Wake Forest Baptist ... edition of Childhood Obesity , found that high-calorie ...
(Date:4/24/2014)... the Center for BrainHealth will bring together national ... brain-related challenges at its inaugural Brain Health Summit, ... Featured speakers will include Dr. Sandra Bond Chapman, ... BrainHealth, U.S. Senator Chuck Grassley (R-IA), U.S. Representative ... Secretary for Policy and Early Learning, U.S. Department ...
Breaking Medicine News(10 mins):Health News:Surprising new insights into the PTEN tumor suppressor gene 2Health News:Surprising new insights into the PTEN tumor suppressor gene 3Health News:Large-scale identification and analysis of suppressive drug interactions 2Health News:Parents of severely ill children see benefits as caregivers, says study 2Health News:Take the bat, leave the candy 2Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2
... The discovery 15 years ago that the genes BRCA1 ... cancer was a breakthrough for cancer prediction and therapy, ... Prof. Alfons Meindl (Klinikum rechts der Isar of the ... Germany, the U.K., and the U.S., can identify another ...
... likely to be screened, study finds , WEDNESDAY, April 21 ... are being screened for skin cancer, a particular problem among ... common cancer screenings, a new study has found. , Researchers ... and older, who took part in the 2005 National Health ...
... ... , ... (Vocus) April 21, 2010 -- SafeShot Technologies, LLC , a leader in safety ... Emeritus Professor of Surgery at Keck School of Medicine, University of Southern California. Dr. ...
... Washington, DC -- For women with hormone receptor-positive breast ... daily dose of an anti-hormone drug will block the ... breast cancer at bay. The treatments work like ... resistant to therapy. With no other treatment options, ...
... clinical trials have shown that non-steroidal anti-inflammatory drugs ... colon cancer and precancerous polyps in humans. Now, ... that an investigational form of naproxen, called nitric ... earliest molecular changes that lead to colorectal cancer ...
... taken a major step forward in the understanding of ovarian ... Researchers have found that patients with hereditary ovarian cancer ... more likely to experience secondary tumours in their liver and ... is better than other patients. In non-hereditary cancer, ovarian ...
Cached Medicine News:Health News:Researchers identify a new breast and ovarian cancer susceptibility gene 2Health News:Few Over 50 Get Skin Cancer Screenings 2Health News:SafeShot Technologies Names Dr. Robert W. Beart as New Chief Executive Officer 2Health News:SafeShot Technologies Names Dr. Robert W. Beart as New Chief Executive Officer 3Health News:1 big problem with many possible solutions 2Health News:1 big problem with many possible solutions 3Health News:1 big problem with many possible solutions 4Health News:1 big problem with many possible solutions 5Health News:1 big problem with many possible solutions 6Health News:1 big problem with many possible solutions 7Health News:Researchers show that nitric oxide-donating naproxen can boost colorectal cancer prevention 2Health News:Ovarian cancer study offers vital clues for new therapies 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: